Regeneron Monoclonal Antibody Data Increases Probability Of COVID-19 Vaccine Success - Morgan Stanley

September 30, 2020 8:46 AM EDT
Get Alerts MRNA Hot Sheet
Price: $434.46 --0%

Rating Summary:
    6 Buy, 8 Hold, 2 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 3 | Down: 3 | New: 7
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Morgan Stanley's BioPharma analyst Matthew Harrison highlighted that Regeneron's (NASDAQ: REGN) initial data testing monoclonal antibody cocktail REGN-COV2 in non-hospitalized SARS-CoV-2 patients increases the probability of success for certain COVID-19 vaccines.

The analyst notes that data from the placebo group demonstrated that individuals that mount an immune response against SARS-CoV-2 (seropositive) achieved a faster alleviation of their symptoms (in ~7 days) compared to seronegative individuals (in ~13 days).

"We believe these data highlight the importance of the humoral immune response in the ability to clear the infection," the analyst said. "Regeneron also presented data suggesting a correlation between serological status and baseline viral load, while demonstrating that REGN-COV2 may compensate for a weak natural-immune response."

"Consequently, these data provide supporting evidence that the humoral immune response and/or neutralizing antibodies could potentially reduce the viral burden and alleviate symptoms faster," Harrison said. "We believe these data partially de-risk the most advanced vaccine candidates targeting the spike protein, while also shedding light on the
unique immune response that defines COVID-19."

Vaccine Stocks:

  • AstraZeneca (NASDAQ: AZN)
  • BioNTech SE (NASDAQ: BNTX)
  • Merck (NYSE: MRK)
  • Moderna (NASDAQ: MRNA)
  • Pfizer (NYSE: PFE)
  • Sanofi (NASDAQ: SNY)
  • Novavax (NASDAQ: NVAX)

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA, Hot Comments, Trader Talk

Related Entities

Morgan Stanley